The increasingly central role of corporate venture, the adaptation of the traditional venture model to the economic times, and the return of the bull market were all raised as themes at this year's BioTrinity conference. OBN is the membership organisation supporting and bringing together the UK's emerging life science companies, corporate partners and investors.
The first day of the conference opened with senior figures from AbbVie, SR One, Boehringer-Ingelheim Venture Fund, Takeda Ventures & MP Healthcare Venture Management and SV Life Sciences Advisors LLP, discussing the significant role corporate venture firms play in providing life science companies with investment and whether they are indispensable to life science funding in a panel entitled Corporate VC 2013. Now Part of the Furniture.